Orchard Therapeutics
MA - Boston
Biotechnology1 H-1B visas (FY2023)Focus: Ex-vivo autologous hematopoietic stem cell gene therapy
Orchard Therapeutics is a life sciences company focused on Ex-vivo autologous hematopoietic stem cell gene therapy.
Cell TherapyGene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Neoplasms, Unknown PrimaryClinical Trials (1)
NCT02628379Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
N/AOSSIX Volumax
Dental ImplantsClinical Trials (1)
NCT06187805Retrospective Case Series - OSSIX Volumax Collagen Xenograft Scaffolding
N/AImaging
MucopolysaccharidosesClinical Trials (1)
NCT05354219Validation and Reliability of Iris Cameras in Mucopolysaccharidoses
N/AConfirmatory Testing
Acid Sphingomyelinase DeficiencyThe Myelin Disorders Biorepository Project
LeukodystrophyVirtual Reality
Old Age; DebilityClinical Trials (1)
NCT04083885Virtual Reality Training to Increase Rehabilitative Exercise in Seniors
N/ABaby Detect : Genomic Newborn Screening
Congenital Adrenal HyperplasiaInfusion of autologous cryopreserved EFS-ADA LV CD34+ cells
Severe Combined Immunodeficiency Due to ADA DeficiencyClinical Trials (1)
NCT02999984Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Phase 1/2Infusion of autologous EFS-ADA LV CD34+
ADA-SCIDClinical Trials (1)
NCT01852071Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene
Phase 1/2Infusion of autologous EFS-ADA LV CD34+ cells
Adenosine Deaminase DeficiencyClinical Trials (1)
NCT01380990Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Phase 1/2OTL-200 Gene Therapy
Lysosomal Storage DiseaseClinical Trials (1)
NCT01560182Gene Therapy for Metachromatic Leukodystrophy (MLD)
Phase 1/2Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene
Beta-ThalassemiaClinical Trials (1)
NCT02453477Gene Therapy for Transfusion Dependent Beta-thalassemia
Phase 1/2Autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene
Mucopolysaccharidosis Type IIIAClinical Trials (1)
NCT04201405Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA
Phase 1/2Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
Severe Combined Immunodeficiency Due to ADA DeficiencyClinical Trials (1)
NCT03765632Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Phase 1/2Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
Mucopolysaccharidosis IHClinical Trials (1)
NCT03488394Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant
Phase 1/2OTL-200
Lysosomal Storage DiseaseClinical Trials (1)
NCT03392987A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)
Phase 2Experimental: OTL-203
MPS-IH (Hurler Syndrome)Clinical Trials (1)
NCT06149403A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Phase 3OTL-200
Lysosomal Storage DiseasesClinical Trials (1)
NCT04283227OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2015
Portfolio: 15 clinical trials
H-1B (2023): 1 approval
Hiring Trend
Stable
0
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub